Previous
Previous

EFFICACY AND SAFETY OF FEZOLINETANT IN MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE: A PHASE 3 RCT

Next
Next

FIRST BOLOGNA, THEN POSEIDON: WHAT ARE WE STILL MISSING TO PERSONALIZE CARE FOR PATIENTS UNDERGOING ASSISTED REPRODUCTIVE TECHNOLOGY WITH A POOR PROGNOSIS?